Company intelligence / Profile preview
APRINOIA Therapeutics
Cambridge, Massachusetts, United Statesaprinoia.com ↗
- Ownership
- Private
- Employees
- ~72
- Development stage
- Other
01
Overview
APRINOIA has received FDA "Study May Proceed" letter for Phase 3 study of APN-1607 (florzolotau) for PSP diagnosis in January 2024. In May 2024, the FDA granted Fast Track Designation for APN-1607. Their therapeutic antibody APNmAb005 received FDA clearance to begin Phase 1 trials in April 2022.
- Therapeutic areas
- Neurology
- Modalities
- PET imaging tracersmonoclonal antibodiessmall moleculesprotein degraders
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Michael J. Fox FoundationLundbeckAbbVieInsilico MedicineAlzheimer's Drug Discovery Foundation (ADDF)
Beyond the preview
Go deeper on APRINOIA Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APRINOIA Therapeutics.